Early Prediction of Lupus Nephritis Using Advanced Proteomics
Annual rept. 1 Jun 2010-31 May 2011
CHILDREN'S HOSPITAL MEDICAL CENTER CINCINNATI OH
Pagination or Media Count:
The purpose of this project is to identify initial biomarker patterns in SLE nephritis using screening proteomic profiling. Subject recruitment has been completed. Utility of one of the biomarkers NGAL in predicting worsening of global and renal SLE disease activity has been validated. We have identified novel urinary biomarkers that distinguish between class IV and class V lupus nephritis, including alpha-1-B glycoprotein by 2D gel electrophoresis, alpha-1-antitrypsin by SELDI-TOF-MS, citrate and taurine by NMR spectroscopy-based metabolomic profiling, and apolipoprotein D, lipocalin-like prostaglandin D synthetase, hemopexin, ceruloplasmin, alpha-1-B glycoprotein and orosomucoid by LC-MSMS profiling. These important findings need validation. First, we need to validate whether these biomarkers are differentially expressed in patients with kidney biopsy-proven lupus nephritis types IV and V. Another important component of validation will be to utilize a different assay to confirm the novel findings on proteomic profiling. These are our goals for the upcoming year. Overall, these studies will identify a subset of non-invasive biomarkers that identify lupus nephritis sub-classes, and predict the clinical course of the disease. The significance of such biomarkers is that they will provide novel non-invasive tools to identify patients with lupus nephritis, to risk-stratify the subjects for therapies, and to follow the efficacy of therapies.
- Medicine and Medical Research